Press Releases

Date Title and Summary  
Toggle Summary Geron Corporation Reports 2007 Second Quarter Financial Results and Events
MENLO PARK, Calif., July 30, 2007 –– Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June 30, 2007. For the second quarter of 2007, the company reported a net loss of $14.0 million, or $(0.19) per share, compared to $5.3 million, or $(0.08) per
Toggle Summary Geron Initiates Clinical Trial of Telomerase Cancer Vaccine in Patients with Acute Myelogenous Leukemia
MENLO PARK, Calif., July 11, 2007 – Geron Corporation (Nasdaq: GERN) announced today the initiation of a clinical trial of its telomerase cancer vaccine, GRNVAC1, in patients with acute myelogenous leukemia (AML) in complete remission. The vaccine is produced from a patient’s blood using a unique
Toggle Summary Geron Initiates Clinical Trial of Telomerase Inhibitor Drug in Combination with Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer
Third Clinical Trial Program for 163L – First Clinical Use in Combination Chemotherapy Ongoing Studies in CLL and Solid Tumors Continue to Accrue Patients MENLO PARK, Calif., July 9, 2007 – Geron Corporation (Nasdaq: GERN) announced today the initiation of a clinical trial of its telomerase
Toggle Summary Geron Corporation to Host Analyst and Investor Meeting in New York City on July 17, 2007
–Event to be Webcast on Geron’s Website– MENLO PARK, Calif., July 5, 2007 – Geron Corporation (Nasdaq: GERN) announced today that it will host an analyst and investor meeting in New York City on Tuesday, July 17, 2007. At the meeting, Alan B. Colowick, M.D., M.P.H., president of Oncology, and Fabio
Toggle Summary Research Documents Scalable Production, Survival Following Engraftment and Positive Impact On Cardiac Function in Infarcted Rats for Geron’s Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
Company's Second Cell Type for Clinical Development – Cardiomyocytes for Treatment of Heart Failure – is Subject of Feature Presentation at ISSCR Annual Meeting Other Presentations Document Continued Progress in Geron's Development of Cellular Products for Spinal Cord Injury, Diabetes and
Toggle Summary Geron Increases Stake in TA Therapeutics Joint Venture
Joint Venture Company is Working Toward Filing of IND for Small Molecule Compound to Treat HIV/AIDS MENLO PARK, Calif., and HONG KONG, June 18, 2007 – Geron Corporation (Nasdaq: GERN) and the Biotechnology Research Corporation (BRC) of Hong Kong today announced that Geron has increased its stake in
Toggle Summary Geron´s Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
Data Presented at Pan Pacific Lymphoma Conference Support Continued Dose Escalation in Ongoing Chronic Lymphocytic Leukemia Trial New Studies in Multiple Myeloma and Non–Small Cell Lung Cancer to Start in the Coming Months MENLO PARK, Calif., June 12, 2007 – Geron Corporation’s (Nasdaq: GERN)
Toggle Summary Geron Corporation to Present at Needham & Company Biotechnology and Medical Technology Conference
MENLO PARK, Calif., Jun. 12, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 8:00 a.m. EDT on Wednesday, June 13, 2007, at the 6th Annual
Toggle Summary Research Indicates Geron´s Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Study Findings Could Mean Significantly Lower Doses and/or Shorter Courses of Immunosuppression for Patients Treated with GRNOPC1 MENLO PARK, Calif., June 11, 2007 – Geron Corporation (Nasdaq: GERN) today announced the presentation of research studies indicating that GRNOPC1, the company’s human
Toggle Summary Geron Corporation to Present at Banc of America Health Care Conference
MENLO PARK, Calif., May 31, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 11:20 a.m. PDT on Friday, June 1, 2007, at the Banc of America 2007